Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07153939

Pivotal Study of the Velocity™ pAVF System

Multicenter Pivotal Study of the Velocity™ Percutaneous Arterio-Venous Fistula System

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
126 (estimated)
Sponsor
Venova Medical · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.

Conditions

Interventions

TypeNameDescription
DEVICEVelocity Percutaneous Arteriovenous FistulaThe Velocity pAVF is a catheter-based device used to create an arteriovenous fistula for hemodialysis access through a minimally invasive, percutaneous procedure. Unlike surgical AVF creation or other pAVF systems, Velocity is designed to simplify the procedure and improve consistency of maturation and long-term function. All participants in this study will undergo AVF creation using the Velocity pAVF.

Timeline

Start date
2025-10-21
Primary completion
2026-09-01
Completion
2030-09-01
First posted
2025-09-04
Last updated
2026-01-30

Locations

10 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07153939. Inclusion in this directory is not an endorsement.